mvjrМедицинский вестник Юга РоссииMedical Herald of the South of Russia2219-80752618-7876The Rostov State Medical University10.21886/2219-8075-2019-10-2-6-12mvjr-826Research ArticleОБЗОРЫREVIEWБезопасность и эффективность применения Омализумаба при бронхиальной астмеSafety and efficiency of using Omaulizumab in bronchial asthmahttps://orcid.org/0000-0002-5129-0402СтрельцовЕ. А.Strel’tsovE. A.

Стрельцов Евгений Александрович - внутренние болезни, врач-интерн

lidigi@mail.ruhttps://orcid.org/0000-0002-0035-3581ДемидовВ. С.DemidovV. S.

Демидов Владислав Сергеевич - внутренние болезни, врач-интерн

Demidovvlad@mail.ruhttps://orcid.org/0000-0001-7134-2428ЦойЛ. В.TsoyL. V.

Цой Людмила Владимировна - внутренние болезни, врач-интерн

Lyudmila V. Tsoy - internal          illnesses, intern doctor

Lyudmila.tsoyy@gmail.comhttps://orcid.org/0000-0003-0439-0846КоровинаМ. Э.KorovinaM. E.

Коровина Мария Эдуардовна - внутренние болезни, врач-интерн

Mariya E. Korovina - internal illnesses, intern doctor

Korovina94@mail.ruhttps://orcid.org/0000-0003-4896-7969РазыщиковаН. М.RazyschikovaN. M.

Разыщикова Надежда Максимовна - внутренние болезни, врач-интерн

miss.2494@bk.ruhttps://orcid.org/0000-0002-7573-0687КаржауоваА. Е.KarzhauovaА. E.

Asel’ E. Karzhauova - internal illnesses, intern doctor

asselya0303@yandex.kzМедицинский университет КарагандыКазахстанKaraganda Medical UniversityKazakhstan201902092019102612Copyright © Стрельцов Е.А., Демидов В.С., Цой Л.В., Коровина М.Э., Разыщикова Н.М., Каржауова А.Е., 20192019Стрельцов Е.А., Демидов В.С., Цой Л.В., Коровина М.Э., Разыщикова Н.М., Каржауова А.Е.Strel’tsov E.A., Demidov V.S., Tsoy L.V., Korovina M.E., Razyschikova N.M., Karzhauova А.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.medicalherald.ru/jour/article/view/826

В настоящем обзоре литературы рассмотрены вопросы эффективности и безопасности терапии омализумабом при бронхиальной астме при помощи рандомизированных исследований последних лет. Подробно освещены механизмы патогенеза бронхиальной астмы, эффективность приема препарата и его побочные эффекты. Рассмотрена эффективность приема омализумаба по следующим ключевым точкам исследований: необходимость применения ингаляционных глюкокортикостероидов, качество жизни пациентов и частота обострений. Системный поиск литературы проводился по базам данных Scopus, Web of Science, MedLine, elibrary и другим.

This review reviews the efficacy and safety of omalizumab therapy in bronchial asthma using randomized trials of recent years. Mechanisms of the pathogenesis of bronchial asthma, the effectiveness of the drug and its side effects are discussed in detail. The effectiveness of omalizumab is considered at the following key research points: the need for inhaled glucocorticosteroids, the quality of patients’ life and the frequency of exacerbations. Systematic literature search was carried out on the databases Scopus, Web of Science, MedLine, elibrary and others.

омализумаббронхиальная астмаэффективностьобзорпатогенезomalizumabbronchial asthmaefficiencyreviewpathogenesisReferencesKubo M. Innate and adaptive type 2 immunity in lung allergic inflammation. // Immunol Rev. - 2017. -V.278(1). - P.162172. doi: 10.1111/imr.12557Kubo M. Innate and adaptive type 2 immunity in lung allergic inflammation. Immunol Rev. 2017;278(1):162-172. doi: 10.1111/imr.12557Nabih E.S., Kamel H.F., Kamel T.B. Association between CD14 polymorphism (-1145G/A) and childhood bronchial asthma. // Biochem Genet. - 2016. - V.54. - P.50-60. doi: 10.1007/s10528-015-9699-4Nabih ES, Kamel HF, Kamel TB. Association between CD14 polymorphism (-1145G/A) and childhood bronchial asthma. Biochem Genet. 2016;54:50-60. doi: 10.1007/s10528-015-9699-4Dissanayake S., Jain M., Grothe B., Mciver T., Papi A. An evaluation of comparative treatment effects with high and low dose fluticasone propionate/formoterol combination in asthma. // Pulm Pharmacol Ther. - 2015. -V.35. - P.19-27. doi: 10.1016/j.pupt.2015.10.001Dissanayake S, Jain M, Grothe B, Mciver T, Papi A. An evaluation of comparative treatment effects with high and low dose fluticasone propionate/formoterol combination in asthma. Pulm Pharmacol Ther. 2015;35:19-27. doi: 10.1016/j.pupt.2015.10.001Crocker D.D. , Kinyota S., Dumitru G.G., Ligon C.B., Herman E.J., Ferdinands J.M. et all. Effectiveness of home-based, multi-trigger, multicomponent interventions with an environmental focus for reducing asthmamorbidity: a community guide systematic review. // Am JPrev Med. - 2011. - V.41(2 Suppl 1). - P.S5-32. doi: 10.1016/j.amepre.2011.05.012Crocker DD , Kinyota S, Dumitru GG, Ligon CB, Herman EJ, Ferdinands JM et all. Effectiveness of home-based, multitrigger, multicomponent interventions with an environmental focus for reducing asthmamorbidity: a community guide systematic review. Am J Prev Med. 2011;41(2 Suppl 1):S5-32. doi: 10.1016/j.amepre.2011.05.012CDC. Asthma: most recent asthma data. 2017. Atlanta, GA: US Department of Health and Human Services, CDC; 2017. https://www.cdc.gov/asthma/most_recent_data.htmCDC. Asthma: most recent asthma data. 2017. Atlanta, GA: US Department of Health and Human Services, CDC; 2017. https://www.cdc.gov/asthma/most_recent_data.htmPatel O., Syamlal G., Wood J., Dodd K.E., Mazurek J.M. Asthma Mortality Among Persons Aged 15-64 Years, by Industry and Occupation - United States, 1999-2016. // MMWR Morb Mortal Wkly Rep. - 2018. - V.67(2). - P.60-65. doi: 10.15585/mmwr.mm6702a2Patel O, Syamlal G., Wood J, Dodd KE, Mazurek JM. Asthma Mortality Among Persons Aged 15-64 Years, by Industry and Occupation - United States, 1999-2016. MMWR Morb Mortal Wkly Rep. 2018;67(2):60-65. doi: 10.15585/mmwr.mm6702a2Masoli M., Fabian D., Holt S., Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. // Allergy. - 2004. - V.59(5). - P.469-78.Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy.2004;59(5):469-78.Tsai M.K., Lin Y.C., Huang M.Y., Lee M.S., Kuo C.H., Kuo P.L. et all. The effects of asthma medications on reactive oxygen species production in human monocytes. // J Asthma. -2017. -V.55(4). - P.345-353. doi: 10.1080/02770903.2017.1339798Tsai MK, Lin YC, Huang MY, Lee MS, Kuo CH, Kuo PL et all. The effects of asthma medications on reactive oxygen species production in human monocytes. J Asthma. 2017;55(4):345-353. doi: 10.1080/02770903.2017.1339798Kaiser S.V., Rodean J., Bekmezian A., Hall M., Shah S.S., Ma-hant S. et all. Pediatric Research in Inpatient Settings (PRIS) Network: Rising utilization of inpatient pediatric asthma pathways. // J Asthma. - 2017. - V.55(2). - P.196-207. doi: 10.1080/02770903.2017.1316392Kaiser SV, Rodean J, Bekmezian A, Hall M, Shah SS, Ma-hant S, et all. Pediatric Research in Inpatient Settings (PRIS) Network: Rising utilization of inpatient pediatric asthma pathways. J Asthma. 2017;55(2):196-207. doi: 10.1080/02770903.2017.1316392Galli S.J. Mast cells and KIT as potential therapeutic targets in severe asthma. // N Engl J Med. - 2017. - V.376(20). - P.19831984. doi: 10.1056/NEJMe1702653.Galli SJ. Mast cells and KIT as potential therapeutic targets in severe asthma. N Engl J Med. 2017;376(20):1983-1984. doi: 10.1056/NEJMe1702653.Fahy J.V. Type 2 inflammation in asthma—present in most, absent in many. // Nat Rev Immunol. - 2015. - V.15. - P.5765. doi: 10.1038/nri3786Fahy JV. Type 2 inflammation in asthma—present in most, absent in many. Nat Rev Immunol. 2015;15:57-65. doi: 10.1038/nri3786Endo Y., Iwamura C., Kuwahara M., Suzuki A., Sugaya K., Tumes D.J. et all. Eomesodermin controls interleukin-5 production in memory T helper 2 cells through inhibition of activity of the transcription factor GATA3. // Immunity. - 2011. - V.35(5). - P.733-45. doi: 10.1016/j.immu-ni.2011.08.017.Endo Y, Iwamura C, Kuwahara M, Suzuki A, Sugaya K, Tumes DJ et all. Eomesodermin controls interleukin-5 production in memory T helper 2 cells through inhibition of activity of the transcription factor GATA3. Immunity. 2011;35(5):733-45. doi: 10.1016/j.immuni.2011.08.017.Nakayama T., Hirahara K., Onodera A., Endo Y., Hosoka-wa H., Shinoda K et all. Th2 cells in health and disease. // Annu Rev Immunol. - 2017. - V.35. - P.53-84. doi: 10.1146/annurev-immunol-051116-052350Nakayama T, Hirahara K, Onodera A, Endo Y, Hosokawa H, Shinoda K et all. Th2 cells in health and disease. Annu Rev Immunol. 2017;35:53-84. doi: 10.1146/annurev-immu-nol-051116-052350Hess C., Kemper C. Complement-mediated regulation of metabolism and basic cellular processes. // Immunity. - 2016. -V.45(2). - P.240-54. doi: 10.1016/j.immuni.2016.08.003.Hess C, Kemper C. Complement-mediated regulation of metabolism and basic cellular processes. Immunity. 2016;45(2):240-54. doi: 10.1016/j.immuni.2016.08.003.Platts-Mills T.A. The role of immunoglobulin E in allergy and asthma. // JRespir Crit Care Med. - 2001. - V.164(8 Pt 2). -P.S1-5.Platts-Mills TA. The role of immunoglobulin E in allergy and asthma. J Respir Crit Care Med. 2001;164(8 Pt 2): S1-5.Sutton B.J, Davies A.M. Structure and dynamics of IgE-re-ceptor interactions: FceRI and CD23/FceRII. // Immunol. Rev. - 2015. - V.268(1). - P.222-35. doi: 10.1111/imr.12340Sutton B J, and Davies AM. Structure and dynamics of IgE-receptor interactions: FceRI and CD23/FceRII. Immunol. Rev. 2015;268(1):222-35. doi: 10.1111/imr.12340Holgate S.T. New strategies with anti-IgE in allergic diseases. // World Allergy Organ. J. - 2014. - V.7(1). - P.17. doi: 10.1186/1939-4551-7-17Holgate ST. New strategies with anti-IgE in allergic diseases. World Allergy Organ. J. 2014;7(1):17. doi: 10.1186/1939-4551-7-17Schulman E.S. Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders. // Am J Respir Crit Care Med. -2001. - V.164. - P.S6-S11.Schulman ES. Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders. Am J Respir Crit Care Med. 2001;164:S6-S11.Pereira Santos M.C., Campos Melo A., Caetano A., Caiado J., Mendes A., Pereira Barbosa M. et all. Longitudinal study of the expression of FceRI and IgE on basophils and dendritic cells in association with basophil function in two patients with severe allergic asthma treated with omalizumab. // Eur Ann Allergy Clin Immunol. - 2015. - V47. - P.38-40.Pereira Santos MC, Campos Melo A, Caetano A, Caiado J, Mendes A, Pereira Barbosa M et all. Longitudinal study of the expression of FceRI and IgE on basophils and dendritic cells in association with basophil function in two patients with severe allergic asthma treated with omalizumab. Eur Ann Allergy Clin Immunol. 2015;47:38-40.Lai T., Wang S., Xu Z., Zhang C., Zhao Y., Hu Y et all. Longterm efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis. // Scientific Reports. - 2015. - V.5. - P.8191. doi: 10.1038/srep08191Lai T, Wang S, Xu Z, Zhang C, Zhao Y, Hu Y et all. Longterm efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis. Scientific Reports. 2015;5:8191. doi: 10.1038/srep08191Sattler C., Garcia G., Humbert M. Novel targets of omalizumab in asthma. // Curr Opin Pulm Med. - 2017. - V.23. - P.56-61.Sattler C, Garcia G, Humbert M. Novel targets of omalizumab in asthma. Curr Opin Pulm Med. 2017;23:56-61.Teach S.J., Gill M.A., Togias A., Sorkness C.A., Arbes S.J., Jr, Calatroni A et all. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. // J Allergy Clin Immunol. - 2015. -V.136. - P.1476-1485.Teach SJ, Gill MA, Togias A, Sorkness CA, Arbes SJ, Jr, Cala-troni A et all. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol. 2015;136:1476-1485.Hayashi H., Mitsui C., Nakatani E., Fukutomi Y., Kajiwara K., Watai K. et all. Omalizumab reduces cysteinyl leukotri-ene and 9a,11p-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease. // J Allergy Clin Immunol. -2016. - V.137. - P.1585-1587.e4.Hayashi H, Mitsui C, Nakatani E, Fukutomi Y, Kajiwara K, Watai K et all. Omalizumab reduces cysteinyl leukotriene and 9a,11p-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2016;137:1585-1587.e4.Fajt M.L., Wenzel S.E. Development of new therapies for severe asthma. // Allergy Asthma Immunol Res. - 2017. - V.9. -P.3-14.Fajt ML, Wenzel SE. Development of new therapies for severe asthma. Allergy Asthma Immunol Res. 2017;9:3-14.Li J., Kang J., Wang C., Yang J., Wang L., Kottakis I. et all. Omalizumab improves quality of life and asthma control in Chinese patients with moderate to severe asthma: a Randomized Phase III Study. // Allergy Asthma Immunol Res. - 2016. - V.8. - P.319-328.Li J, Kang J, Wang C, Yang J, Wang L, Kottakis I et all. Omali-zumab improves quality of life and asthma control in Chinese patients with moderate to severe asthma: a Randomized Phase III Study. Allergy Asthma Immunol Res. 2016;8:319-328.Kuprys-Lipinska I., Molinska K., Kuna P. The effect of omalizumab on eosinophilic inflammation of the respiratory tract in patients with allergic asthma. // Pneumonol Alergol Pol. - 2016. - V.84. - P.232-243.Kuprys-Lipinska I, Molinska K, Kuna P. The effect of omali-zumab on eosinophilic inflammation of the respiratory tract in patients with allergic asthma. Pneumonol Alergol Pol. 2016;84:232-243.Carr T.F., Berdnikovs S., Simon H.U., Bochner B.S., Rosenwasser L.J. Eosinophilic bioactivities in severe asthma. // World Allergy Organ J. - 2016. - V.9. - P.21.Carr TF, Berdnikovs S, Simon HU, Bochner BS, Rosenwasser LJ. Eosinophilic bioactivities in severe asthma. World Allergy Organ J. 2016;9:21.de Llano L.P., Vennera M.C., Alvarez F.J., Medina J.F., Bor-derias L., Pellicer Cet all. Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry. // J Asthma. - 2013. - V.50. - P.296-301.de Llano LP, Vennera MC, Alvarez FJ, Medina JF, Borderias L, Pellicer C et all. Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry. J Asthma. 2013;50:296-301.Garcia G., Magnan A., Chiron R., Contin-Bordes C., Berger P., Taille C. et all. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. // Chest. - 2013. - V.144. - P.411419.Garcia G, Magnan A, Chiron R, Contin-Bordes C, Berger P, Taille C et all. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-con-trol, nonatopic asthma. Chest. 2013;144:411-419.Pillai P., Chan Y.C., Wu S.Y., Ohm-Laursen L., Thomas C., Durham S.R. et all. Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma. // Eur Respir J. - 2016. - V.48. - P.1593-1601.Pillai P, Chan YC, Wu SY, Ohm-Laursen L, Thomas C, Durham SR et all. Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma. Eur Respir J. 2016;48:1593-1601.Chen H.C., Huang C.D., Chang E., Kuo H.P. Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study. // BMC Pulmonary Medicine. -2016. - V.16. - P.3. doi: 10.1186/s12890-015-0156-2Chen HC, Huang CD, Chang E, Kuo HP. Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study. BMC Pulmonary Medicine. 2016;16:3. doi: 10.1186/s12890-015-0156-2Niven R.M., Saralaya D., Chaudhuri R., Masoli M., Clifton I., Mansur A.H. et all. Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study). // BMJ Open. - 2016. - V.6(8). - P.e011857. doi: 10.1136/bmjopen-2016-011857Niven RM, Saralaya D, Chaudhuri R, Masoli M, Clifton I, Mansur AH et all. Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study). BMJ Open. 2016 ;6(8):e011857. doi: 10.1136/bmjopen-2016-011857Donald D.W. Asthma and Therapeutics: Recombinant Therapies in Asthma. // Allergy Asthma Clin Immunol. -2005. - V.1(1). - P.34-41. doi: 10.1186/1710-1492-1-1-34Donald DW. Asthma and Therapeutics: Recombinant Therapies in Asthma. Allergy Asthma Clin Immunol. 2005;1(1):34-41. doi: 10.1186/1710-1492-1-1-34Scichilone N., Ventura M.T., Bonini M., Braido F., Bucca C., Caminati M. et all. Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly. // Clin Mol Allergy. - 2015. - V.13(1). - P.7. doi: 10.1186/s12948-015-0016-xScichilone N, Ventura MT, Bonini M, Braido F, Bucca C, Cam-inati M et all. Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly. Clin Mol Allergy. 2015;13(1):7. doi: 10.1186/s12948-015-0016-xSposato B., Scalese M., Latorre M., Scichilone N., Matucci A., Milanese M. et all. Effects of omalizumab in severe asthmatics across ages: A real life Italian experience. // Respir Med. -2016. - V.119. - P.141-149. doi: 10.1016/j.rmed.2016.09.005Sposato B, Scalese M, Latorre M, Scichilone N, Matucci A, Milanese M et all. Effects of omalizumab in severe asthmatics across ages: A real life Italian experience. Respir Med. 2016;119:141-149. doi: 10.1016/j.rmed.2016.09.005Odajima H., Ebisawa M., Nagakura T., Fujisawa T., Akasawa A., Ito K. et all. Long-term safety, efficacy, pharmacokinetics and pharmacodynamics of omalizumab in children with severe uncontrolled asthma. // Allergol Int. - 2017. - V66(1). -P.106-115. doi: 10.1016/j.alit.2016.06.004Odajima H, Ebisawa M, Nagakura T, Fujisawa T, Akasawa A, Ito K et all. Long-term safety, efficacy, pharmacokinetics and pharmacodynamics of omalizumab in children with severe uncontrolled asthma. Allergol Int. 2017;66(1):106-115. doi: 10.1016/j.alit.2016.06.004Al-Ahmad M., Arifhodzic N., Nurkic J., Maher A., Rodriguez-Bouza T., Al-Ahmed N. et all. “Real-life” Efficacy and Safety Aspects of Four-year Omalizumab Treatment for Asthma. // Med Princ Pract. - 2018. doi: 10.1159/000487482Al-Ahmad M, Arifhodzic N, Nurkic J, Maher A, Rodriguez-Bouza T, Al-Ahmed N et all. “Real-life” Efficacy and Safety Aspects of Four-year Omalizumab Treatment for Asthma. Med Princ Pract. 2018. doi: 10.1159/000487482Foroughi S., Foster B., Kim N., Bernardino L.B., Scott L.M., Metcalfe D.D. et all. (2007) Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. // J Allergy Clin Immunol. - 2007. - V.120(3). - P.594-601.Foroughi S, Foster B, Kim N, Bernardino LB, Scott LM, Metcalfe DD et all. (2007) Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. J Allergy Clin Immunol. 2007;120(3):594-601.Di Bona D., Fiorino I., Taurino M., Frisenda F., Minenna E., Pasculli C. et all. Long-term «real-life» safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study. // Respir Med. - 2017. - V.130. - P.55-60. doi: 10.1016/j.rmed.2017.07.013Di Bona D, Fiorino I, Taurino M, Frisenda F, Minenna E, Pasculli C et all. Long-term «real-life» safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study. Respir Med. 2017;130:55-60. doi: 10.1016/j.rmed.2017.07.013Simpson C.R., Sheikh A. Trends in the epidemiology of asthma in England: a national study of 333,294 patients. // J R Soc Med. - 2010. - V.103. - P.98-106. doi:10.1258/jrsm.2009.090348Simpson CR, Sheikh A. Trends in the epidemiology of asthma in England: a national study of 333,294 patients. J R Soc Med. 2010;103:98-106. doi:10.1258/jrsm.2009.090348Odajima H., Ebisawa M., Nagakura T., Fujisawa T., Akasawa A., Ito K. et all. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy. // Allergol Int. - 2015. - V64(4). - P.364-70. doi: 10.1016/j.alit.2015.05.006.Odajima H, Ebisawa M, Nagakura T, Fujisawa T, Akasawa A, Ito K et all. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy. Allergol Int. 2015;64(4):364-70. doi: 10.1016/j.alit.2015.05.006.Iribarren C., Rahmaoui A., Long A.A., Szefler S.J., Bradley M.S., Carrigan G. et all. Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma. // J Allergy Clin Immunol. - 2017. - V.139(5). -P.1489-1495.e5. doi: 10.1016/j.jaci.2016.07.038.Iribarren C, Rahmaoui A, Long AA, Szefler SJ, Bradley MS, Carrigan G et all. Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma. J Allergy Clin Immunol. 2017;139(5):1489-1495.e5. doi: 10.1016/j.jaci.2016.07.038.Li J., Kang J., Wang C., Yang J., Wang L., Kottakis I. et all. Omalizumab Improves Quality of Life and Asthma Control in Chinese Patients With Moderate to Severe Asthma: A Randomized Phase III Study. // Allergy Asthma Immunol Res. -2016. - V.8(4). - P.319-28. doi: 10.4168/aair.2016.8.4.319Li J, Kang J, Wang C, Yang J, Wang L, Kottakis I, Humphries M et all. Omalizumab Improves Quality of Life and Asthma Control in Chinese Patients With Moderate to Severe Asthma: A Randomized Phase III Study. Allergy Asthma Immunol Res. 2016;8(4):319-28. doi: 10.4168/aair.2016.8.4.319Hide M., Igarashi A., Yagami A., Chinuki Y., Inomata N., Fu-kunaga A. et all. Efficacy and safety of omalizumab for the treatment of refractory chronic spontaneous urticaria in Japanese patients: Subgroup analysis of the phase 3 POLARIS study. // Allergol Int. - 2017. - P.S1323-8930(17)30154-5. doi: 10.1016/j.alit.2017.10.001Hide M, Igarashi A, Yagami A, Chinuki Y, Inomata N, Fuku-naga A et all. Efficacy and safety of omalizumab for the treatment of refractory chronic spontaneous urticaria in Japanese patients: Subgroup analysis of the phase 3 POLARIS study. Allergol Int. 2017:S1323-8930(17)30154-5. doi: 10.1016/j.alit.2017.10.001

The authors declare that there are no conflicts of interest present.